Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I

Experimental and Therapeutic Medicine

Volumn 3, Issue 6, 2012, Pages 925-930

  Ito, Gentaro ^a   Tanaka, Hiroaki ^a   Ohira, Masaichi ^a   Yoshii, Mami ^a   Muguruma, Kazuya ^a   Kubo, Naoshi ^a   Yashiro, Masakazu ^a   Yamada, Nobuya ^a   Maeda, Kiyoshi ^a   Sawada, Tetsuji ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastric cancer; MHC class I; PSK immunochemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; DOXIFLURIDINE; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IMMUNOMODULATING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLANT EXTRACT; PROTEIN BOUND POLYSACCHARIDE K; UFT; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GASTROSCOPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STOMACH CANCER; STOMACH SURGERY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84859476851     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.537     Document Type: Article

References (25)

1. Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820, 2007.
2. Zhang H, Morisaki T, Matsunaga H, et al: Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs. Clin Exp Metastasis 18: 343-352, 2000.
3. Kanazawa M, Yoshihara K, Abe H, et al: Effects of PSK on T and dendritic cell differentiation in gastric or colorectal cancer patients. Anticancer Res 25: 443-449, 2005.
4. Zhang H, Morisaki T, Nakahara C, et al: PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene 22: 2088-2096, 2003.
5. Nakazato H, Koike A, Saji S, Ogawa N and Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study group of immunochemotherapy with PSK for gastric cancer. Lancet 343: 1122-1126, 1994.
6. Cabrera T, Lara E, Romero JM, et al: HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother56: 709-717, 2007.
7. Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K and Aikou T: HLA-class I expression in gastric cancer. J Surg Oncol 97: 605-608, 2008.
8. Lee HW, Min SK, Ju YS, et al: Prognostic significance of HLA class I expressing in gastric carcinoma defined by monoclonal anti-pan HLA class I antibody, EMR8-5. J Gastrointest Surg 15: 1336-1343, 2011.
9. Liu Q, Hao C, Su P and Shi J: Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression. Scand J Gastroenterol 44: 960-969, 2009.
10. 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Gastric Cancer 14: 13-21, 2011.
11. Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P and Meyer HJ: Prognostic factors in gastric carcinoma. Results of the German gastric carcinoma study 1992. Cancer 72: 2089-2097, 1993.
12. Sakcak I, Yildiz BD, Avsar FM, et al: Does N ratio affect survival in D1 and D2 lymph node dissection for gastric cancer? World J Gastroenterol 17: 4007-4012, 2011.
13. Kim JS, Kim MA, Oh DY, et al: Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study. Jpn J Clin Oncol 41: 245-252, 2011.
14. Saito H, Fukumoto Y, Osaki T, et al: Prognostic significance of level and number of lymph node metastases in patients with gastric cancer. J Surg Oncol 14: 1688-1693, 2007.
15. Funada T, Kochi M, Yamazaki S, Fujii M and Takayama T: Prognostic significance of a new system for categorization of the number of lymph node metastases in gastric cancer. Hepatogastroenterology 58: 642-646, 2011.
16. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 411: 380-384, 2001.
17. Mizukami Y, Kono K, Maruyama T, et al: Downregulation of HLA class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer 99: 1462-1467, 2008.
18. Seliger B, Hohne A, Knuth A, et al: Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 56: 1756-1760, 1996.
19. Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M and Durrant LG: Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut59: 926-933, 2010.
20. Shen YQ, Zhang JQ, Miao FQ, et al: Relationship between the downregulation of HLA class I antigen and clinicopathological significance in gastric cancer. World J Gastroenterol 11: 3628-3631, 2005.
21. Lee TB, Min YD, Lim SC, et al: Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells. J Gastroenterol Hepatol 17: 32-38, 2002.
22. Zhou F: Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol 28: 239-260, 2009.
23. Vanky F, Wang P and Klein E: The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells. Cancer Immunol Immunother 35: 193-198, 1992.
24. Pedrinaci S, Algarra I and Garrido F: Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line. Int J Clin Lab Res 29: 135-140, 1999.
25. Sakai T, Yamashita Y, Maekawa T, Mikami K, Hoshino S and Shirakusa T: Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer. Cancer Biother Radiopharm 23: 461-467, 2008.